Browse

As drug hunting gets more complex, where and how data is generated in partnerships between Big Pharmas and AI biotechs is becoming a headache for dealmakers.

A new survey reveals 24% of U.S. workers stay in unwanted jobs to keep health insurance. Experts call it 'job lock.'

With a Phase 3 failure denting the rare disease drug’s prospects, AstraZeneca has little room for error as it plots a path toward its ambitious 2030 sales target.